Fortress Biotech vs Spero Therapeutics
Spero Therapeutics reported revenue of $67 million in fiscal 2025, about the same as Fortress Biotech's $63 million in fiscal 2025. Fortress Biotech's revenue grew 9.7% in its latest year, and Spero Therapeutics' grew 39.2%. Fortress Biotech had an operating margin of -111.0%, against 9.4% at Spero Therapeutics.
Side by side
| Fortress Biotech | Spero Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $63M | $67M |
| Revenue growth | 9.7% | 39.2% |
| Revenue growth a year, last 5 years | 6.8% | 48.3% |
| Gross margin | 66.9% | — |
| Operating margin | −111.0% | 9.4% |
| Net margin | 10.8% | 12.8% |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Return on capital | −323.7% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $1M | $0M |
| Change in diluted share count | 34.2% | 9.3% |
| Last close | $1.77 | $0.83 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $340,398, sold $0 | sold $456,601 |
| Piotroski F-score | 6 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Fortress BiotechSpero Therapeutics
Operating margin
Percent of revenue
Fortress BiotechSpero Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Fortress BiotechSpero Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Fortress Biotech and Spero Therapeutics pages.